Invest in WinSanTor

Developing The First Disease Modifying Drug to Regenerate Peripheral Nerves

FIRST GOAL HIT (You can still invest)

$183,502

raised from 47 investors
INVESTMENT TERMS
Future Equity
$500M valuation cap
$250, $500, $1K, $10K

Highlights

1
Drug regenerating peripheral nerves (humans) - combating direct cause of peripheral neuropathy
2
Repurposed medication w/ UNPARALLELED safety profile in FINAL phase (PH3) of clinical studies (DPN)
3
UNMET need affecting 100s of millions, ignored/neglected by industry, e.g., few, if any, competitors
4
VALIDATED science rewarded by innovation grants (>$40M) and licensing deal (>$200M + royalty)

Featured Investor

Our Team

WinSanTor was not started as a typical company. Similar to the COVID story (infectious diseases), peripheral neuropathy was neglected by industry (and investors). The leading stakeholders gathered and funded the top researchers in DPN to find solutions. We were lucky. They just happened to discover a way to regenerate nerves, thus WST.

Pitch



























Overview